These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8305535)

  • 1. DNA-topoisomerase inhibitors.
    D'Incalci M
    Curr Opin Oncol; 1993 Nov; 5(6):1023-8. PubMed ID: 8305535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
    Utsugi T; Mattern MR; Mirabelli CK; Hanna N
    Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
    Robson CN; Hoban PR; Harris AL; Hickson ID
    Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
    Snyder RD
    Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of DNA topoisomerase inhibitors.
    Binaschi M; Zunino F; Capranico G
    Stem Cells; 1995 Jul; 13(4):369-79. PubMed ID: 7549896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of 9-anilinoacridines as inhibitors of human DNA topoisomerase II.
    Figgitt DP; Denny WA; Gamage SA; Ralph RK
    Anticancer Drug Des; 1994 Jun; 9(3):199-208. PubMed ID: 8031452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
    Baloch Z; Cohen S; Coffman FD
    J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cationic porphyrins and analogues as new DNA topoisomerase I and II inhibitors.
    Shuai L; Wang S; Zhang L; Fu B; Zhou X
    Chem Biodivers; 2009 Jun; 6(6):827-37. PubMed ID: 19551725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin.
    Montaner B; Castillo-Avila W; Martinell M; Ollinger R; Aymami J; Giralt E; Pérez-Tomás R
    Toxicol Sci; 2005 Jun; 85(2):870-9. PubMed ID: 15788728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
    Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
    Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
    Boege F
    Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
    Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
    Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
    Leteurtre F; Madalengoitia J; Orr A; Guzi TJ; Lehnert E; Macdonald T; Pommier Y
    Cancer Res; 1992 Aug; 52(16):4478-83. PubMed ID: 1322792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.